Method of treatment of liver steatosis in cats

FIELD: veterinary medicine.

SUBSTANCE: method comprises complex pathogenetic therapy. Additionally, the specific biological preparation is used. The preparation is prepared according to the principle of production of cytotoxic serum from donor blood by hyperimmunisation of their antigens prepared from liver and spleen tissue. The antihepatotoxic serum and serum antisplenotoxic serum are obtained. They are mixed with sterile saline solution preserved with phenol to 0.5% concentration on the basis of the content in 1.0 ml of 0.9-1.15 its titrated units of antihepatotoxic and antisplenotoxic sera by reaction of binding the complement. The preparation is administered to animals once subcutaneously in the area of the withers at a dose of 0.45-1.1 ml per 1 kg of live weight. The method provides a higher immune status of the animal organism and high efficacy of treatment.

EFFECT: invention enables to improve the efficiency of treatment of liver steatosis in cats.

4 tbl, 1 ex

 

The invention relates to veterinary medicine, in particular veterinary therapy, and can be used for the treatment of fatty hepatosis cats.

In veterinary medicine there are several different ways to treat fatty hepatosis cats.

There is a method of treatment of fatty hepatosis cats, including in addition to the pathogenetic therapy of drug use Essentiale Forte in injectable form. The drug is injected in the following dosages: 0,05-0,1 ml per 1 kg of live weight. Treatment is 5-7 days.

The disadvantage of this method is the lack of an evidence base on the effectiveness of Essentiale Forte in the treatment of fatty hepatosis in cats.

There is a method of treatment of fatty hepatosis cats, consisting in the use of the drug "Gepatit". The product contains phospholipids, methionine, L-ornithine, extract, milk Thistle and grass Immortelle. Gepatit is given orally in a dose of 0.3 ml/kg of body weight cats for 30 minutes before feeding. Gepatit apply three times a day for 30 days. The disadvantage of this method is a long course of treatment [1].

There is a method of treatment of fatty hepatosis cats with the drug Heptral. It is recommended to assign intramuscularly or intravenously in a daily dose of 100-200 mg Duration of intensive therapy Heptral 2-3 weeks of treatment. N the prosperity of this method is a long course of treatment, as well as the high cost of the drug [2].

The aim of the invention is to increase the effectiveness of specific treatment of fatty hepatosis cats. This is achieved by the fact that the complex pathogenetic therapy include drug, with the title: "Garim for cats", which is injected animals once subcutaneously in the region of the withers at a dose of 0.45-1.1 ml per 1 kg of body weight. The dose of injection was determined experimentally.

The drug is transparent, slightly opalescense, straw-yellow with a reddish tint liquid containing 1 ml of 0.9-1,15 tetrofosmin units antihepatotoxic and antiperoxidase sera by the reaction of complement fixation.

Check the conformity of the method is the requirement of novelty shows that the prior art is not known similar methods of treatment of fatty hepatosis cats. The claimed method meets the requirement of inventive step, as for the specialist it is not obvious from the prior art. The introduction of the drug, obtained according to the principle of the manufacture of cytotoxic serum [3] from the blood donor animals by hyperimmunization their antigen prepared from the tissues of the liver and spleen, is not obvious to a specialist. The drug has a stimulating effect not only on hepatic tissue, n is, especially in the immune system.

This invention can be used in the treatment of fatty hepatosis cats.

The technology of reception of a preparation "Garim for cats" is based on the principle of receiving cytotoxic serum from the blood donor animals by hyperimmunization antigens prepared from the tissues of the liver and spleen.

Scheme for preparation of "Garim for cats" consists of the following steps:

1. Obtaining antigen from the liver. For preparation of antigen from the liver to use the liver of cats. Pieces of liver 4-6 times washed from the blood of 10-fold volume of isotonic sodium chloride solution. The pieces are crushed, pounded in a mortar with glass and throw a 0.85% solution of sodium chloride to 10%concentration. The resulting suspension is centrifuged 9-10 minutes at 2500-3000 rpm and as antigen use the supernatant liquid. Antigen lighten five times freezing and thawing, followed by centrifugation at 7000-8000 rpm for 10 minutes. Keep the antigen in frozen state.

2. Obtaining antigen from the spleen. For preparation of antigen from the spleen using the spleen of the cat. Pieces spleen 4-6 times washed from the blood of 10-fold volume of isotonic sodium chloride solution. The pieces are crushed, pounded in a mortar with glass and bred 085% solution of sodium chloride to 10%concentration. The resulting suspension is centrifuged 9-10 minutes at 2500-3000 rpm and as antigen use the supernatant liquid. Antigen lighten five times freezing and thawing, followed by centrifugation at 7000-8000 rpm for 9-10 minutes. Keep the antigen in frozen state.

3. The choice of the donor animals. For cooking "Garim for cats" as a donor is suitable for the following species: horses, rabbits, cattle and small cattle. Donors must be free from infectious diseases and undergo quarantine.

4. Getting antihepatotoxic serum. Antihepatotoxic serum produced by hyperimmunization donors under the scheme: the first injection of antigen is performed subcutaneously in the region of the left scapula and right popliteal fossa; the second introduction after 6-8 days subcutaneously in the right shoulder blade and the left popliteal fossa; the third injection is carried out through the same period as second - intravenously and subcutaneously in the above point. After 6-8 days after the third injection of the antigen test blood sampling and determine the titer obtained antihepatotoxic serum in the reaction of complement fixation. If there titer of at least 1:160-1:200 conduct blood sampling. The resulting blood is placed in a thermostat at 29-30 minutes at 37-38°C, then under sterile conditions to separate SSU the current from the walls and leave the tube in the refrigerator for better retraction of the clot until the next day. The resulting serum is sucked off and canned phenol 0.5%concentration of the substance in the serum.

5. Getting antiperoxidase serum. Antiperoxidase serum produced by hyperimmunization donors under the scheme: the first injection of antigen is performed subcutaneously in the region of the left scapula and right popliteal fossa; the second introduction after 6-8 days subcutaneously in the right shoulder blade and the left popliteal fossa; the third injection is carried out through the same period as second - intravenously and subcutaneously in the above point. After 6-8 days after the third injection of the antigen test blood sampling and determine the titer obtained antiperoxidase serum in the reaction of complement fixation. If there titer of at least 1:160-1:200 conduct blood sampling. The resulting blood is placed in a thermostat at 29-30 minutes at 37-38°C, then under sterile conditions to separate the clot from the wall and leave in the fridge for better retraction of the clot until the next day. The resulting serum is sucked off and canned phenol 0.5%concentration of the substance in the serum.

6. Receiving means for treatment of laboratory cats. To obtain funds for the treatment of laboratory cats antihepatotoxic, antiperoxidase serum is mixed with sterile saline solution, canned phenol to a 5%concentration so as to 1.0 ml was kept for the 0.9-1,15 tetrofosmin units antihepatotoxic and antiperoxidase sera by the reaction of complement fixation.

Example:

To examine the efficacy of a treatment for fatty hepatosis cats on the basis of the veterinary clinic of the city of Magnitogorsk "Biovet" held experience. To do this came from a fatty hepatosis cats was formed 2 groups of 10 animals. In the first group, which is the control, all animals received conventional treatment for fatty liver steatosis. It included:

1. Supportive therapy - intravenous infusion:

a. Salt solutions: saline, ringer's solution at a rate of 10-20 ml/kg depending on the degree of dehydration.

b. Nutrient solutions: glucose 5%, Dualit based 6-20 ml/kg depending on the degree of exhaustion.

2. Vitamin therapy: catosal, the rate of 0.5 to 2.5 ml per animal depending on the individual state, ascorbic acid at a dose of 0.05-0.1 ml/kg

3. Hepatoprotective therapy - Essentiale Forte N at a dose of 0.05 ml/kg intravenous bolus.

4. Antibiotics - amoxicillin (Clamoxyl LA) at a rate of 1 ml per 10 kg of weight.

5. Antiemetic drugs if necessary reglan rate of 0.05 ml/kg

Treatment in the second group of animals (experienced) differed from the first the second (control) replacement of hepatoprotector Essentiale Forte N developed drug for the treatment of fatty hepatosis "Garim for cats"

The physiological condition of the liver was assessed by biochemical parameters of blood serum. Blood was taken at admission to the clinic and through the month. Was assessed by indicators such as: glucose, Alt, AST, total bilirubin, alkaline phosphatase, creatinine, urea and alpha-amylase. In addition, it was estimated the total period of treatment, as well as the timing of the improvements.

The period of treatment in animals of the control group averaged 10.9 per day, and the offensive improvements - 5.8 day. At that time the experimental animals these periods amounted to 8.6 and 4.1 days, respectively. Therefore, the recovery period the animals of the experimental group by 26.7% was shorter than in animals of the control group. In addition, in the control group 2 animals did not respond to treatment and died on 7 and 12 day, which amounted to 20%. While in the experimental group deaths were noted.

The second group of animals was experienced and in addition to the General scheme of treatment described above (except Essentiale Forte), received in the form of specific treatment "Garim for cats". The drug was administered once subcutaneously in the region of the withers at a dose of 0.5 ml per 1 kg of live weight.

The following is the output of biochemical studies of blood serum of both groups of animals.

1. The initial results of biochemical analysis of blood serum of animals control of InEU group

IndexNormaThe average value of the group of animals
Alanine aminotransferase, U/l20-85416,9±85,91
Aspartate aminotransferase, U/l10-50289,9±42,47
The total bilirubin, µmol/l0,5-1042,7±8,19
Creatinine, µmol/l50-160132,9±8,21
Urea, mmol/l5,5-1110,7±1,05
Alkaline phosphatase, U/l13-150588,1±38,37
Glucose, mmol/l2,6-8,46,7±0,65
Alpha-amylase, U/l531-16601506,9±225,93

2. Secondary results of biochemical studies of blood serum of animals of the control group

IndexNormaThe average value of the group of animals
Alanine aminotransferase, U/l20-85233,0±45,61
Aspartate aminotransferase, U/l10-50156,1±18,13
The total bilirubin, µmol/l0,5-1023,3±2,99
Creatinine, µmol/l50-160124,0±8,95
Urea, mmol/l5,5-119,7±0,52
Alkaline phosphatase, U/l13-150338,8±24,07
Glucose, mmol/l2,6-8,46,8±0,43
Alpha-amylase, U/l531-16601383,5±203,41

p> From tables 1 and 2 shows that there has been an overall decrease of all parameters. So, the value of alanine aminotransferase decreased 1.8 times the value of the aspartate aminotransferase - 1.9 times, the value of bilirubin 1.8 times, alkaline phosphatase - 1.7 times. The value of creatinine decreased by 7.2%, the value of urea - 10.3%, alpha-amylase - 8.9%. The glucose level in the first and the second case has identical parameters.

3. The initial results of biochemical analysis of blood serum of animals of the experimental group

IndexNormaThe average value of the group of animals
Alanine aminotransferase, U/l20-85577,7±89,88
Aspartate aminotransferase, U/l10-50357,9±43,67
The total bilirubin, µmol/l0,5-1053,6±9,59
Creatinine, µmol/l50-160135,5±8,89
Urea, mmol/l5,5-119,9±0,49
Saloon what I phosphatase, U/l13-150815,7±180,00
Glucose, mmol/l2,6-8,46,8±0,32
Alpha-amylase, U/l531-16602559,0±224,40

4. Secondary results of biochemical studies of blood serum of animals of the experimental group

IndexNormaThe average value of the group of animals
Alanine aminotransferase, U/l20-85of 225.6±17,31
Aspartate aminotransferase, U/l10-50152,8±15,02
The total bilirubin, µmol/l0,5-1021,6±2,66
Creatinine, µmol/l50-160141,4±8,43
Urea, mmol/l5,5-1110,7±0,76
Alkaline phosphatase, U/l13-1502501±30,07
Glucose, mmol/l2,6-8,46,0±0,28
Alpha-amylase, U/l531-16602465,0±188,15

From the results of tables 3 and 4 shows that the values of the following indicators declined significantly, alanine aminotransferase 2.6 times, aspartate aminotransferase, and 2.3 times, bilirubin 2.5 times, alkaline phosphatase - 3.3 times. The alpha-amylase decreased by 3.8%. In turn, the performance of the kidneys, such as creatinine and urea, showed a slight increase. So, the value of creatinine rose by 4.4%, and urea by 8.1%. The blood glucose level fell by 13.3%.

Thus, the use of the drug "Garim for cats reduces the recovery period by 26.7%. In addition, its usage is a significant improvement in biochemical indices of blood serum is responsible for the liver, compared with the standard regimen used in the veterinary clinic. This suggests that the use of the drug "Garim for cats" in the complex pathogenetic therapy of fatty hepatosis cats increases the effectiveness of the treatment.

Sources of information

1. Klimov PV, Fedosov A.A. Efficiency of the new hepatoprotective is Reparata "Gepatit" in the treatment of laboratory dogs and cats: the problems of normative-legal regulation in veterinary medicine, 2011; N2. - P.42-44.

2. Gary D. Norsworthy The Feline Patient. Fourth Edition. Wiley-Blackwell. A John Willey & Sons, Inc., Publication 2010. - 1052 p.

3. Action-specific cytotoxic sera on the sex gland / Y.A. Spasokukotsky, NV, Ilicevic, LI Barchenko, O.V., Nascimento, T.M. Zelensky, A.G. Gonorovski. - Kiev: Naukova Dumka, 1977. - 216 C.

The treatment of fatty hepatosis cats, including complex pathogenetic therapy, characterized in that it further apply specific biological preparation which is prepared on the principle of production of cytotoxic serum from blood donors by hyperimmunization their antigens prepared from the tissues of the liver and spleen; get antihepatotoxic serum and antiperoxidase serum, mixed with sterile saline solution, canned phenol 0.5%concentration based content in 1.0 ml of him from 0.9 to 1.15 titrated units antihepatotoxic and antiperoxidase sera by the reaction of complement fixation, the drug is administered to the animals once subcutaneously in the region of the withers at a dose of 0.45-1.1 ml 1 kg of live weight.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a therapeutic agent for preventing and treating chronic liver diseases. The above agent represents amaranth oil prepared by cold pressing of amaranth seed kernels and coats, to be used in a dose of 62.5 - 250 mg/kg of body weight.

EFFECT: declared invention provides higher positive effect on biochemical processes in blood and liver tissues in treating toxic hepatitis.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves simulating hepatitis by 7-day alcoholisation in female rats. A hepatoprotective agent is presented by an api-phytocomposition in the form of an aqueous suspension of honey, lecithin and licorice root extract in the ratio of 10:2:1. The composition is introduced twice a day intragastrically before feeding in a dose of 200 mg/kg of body weight 5 days before ethanol introduction and for 7 days one hour before ethanol introduction.

EFFECT: effective treatment of hepatitis with no side effects.

1 ex, 1 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a pharmaceutical, dietary, nutritional orally soluble composition for peroral intake, which contains at least one S-adenosylmethyonine (SAMe) salt in a combination with physiologically acceptable excipients and optionally other active ingredients. The physiologically acceptable excipients include light magnesium oxide.

EFFECT: compositions of the claimed invention have high taste qualities, which provides easier peroral introduction The compositions by the invention are characterised by the higher systemic bioavailability of S-adenosylmethyonine.

15 cl, 2 dwg, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of pharmaceutics. An extract of Fraxinus excelsior seeds, capable of activating PPAR-alpha, which contains nuzhenide GI3, oleoside methyl ester, excelside B, GI5, salidroside, in effective quantities. An application of the extract of Fraxinus excelsior seeds to obtain a medication for treating a state, in which the PPAR-alpha activation is useful, is described. Also described is a method of treating a subject with the state, in which the PPAR-alpha activation is useful. A method of obtaining the extract of Fraxinus excelsior seeds is disclosed.

EFFECT: application of the claimed extract makes it possible to treat states, in which the PPAR-alpha activation is useful in an efficient way.

14 cl, 11 dwg, 2 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: viral hepatitis in simulated in laboratory animals (rats) with D-galactosamine. Hepatitis is treated by single oral administration of immobilised hyaluronidase 25 unit/kg. Administration either precedes simulation, or is combined with the beginning of stimulation.

EFFECT: method enables reducing a severity of metabolic and morphological hepatic disorders effectively in stimulating hepatitis identical to viral hepatitis in a human with underlying reduced xenobiotic load on the body.

1 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula II, methods of producing a compound of formula I

and formula II

,

a pharmaceutical composition and versions of use for treating inflammation and/or liver damage. In the compound of formula II, R1 is H; R2 is a linear or branched C1-C18alkoxy; C-18 is in an α-configuration.

EFFECT: high efficiency of the method.

18 cl, 7 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of obtaining a preparation, possessing a hepatoprotective action. The method of obtaining the preparation, possessing the hepatoprotective action consists in extraction of crushed corn styles with stigmas with ethyl alcohol by a method of multi-step countercurrent extraction with completed cycle in a battery of 5 diffusers, a waste raw material is additionally extracted in 4 and 5 diffusers with an applied extractant, after which it is poured out and passed through 5 diffuser, and kept for a specified time; then, the waste raw material is pressed, the combined extract is settled, the purified extract is condensed under vacuum, dried in a vacuum oven until the dry extract is obtained and crushed under specified conditions.

EFFECT: method is effective for obtaining a stable preparation with the expressed hepatoprotective action.

14 dwg

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering to the animals in the supine position, in addition to the general course of treatment during 5-7 days of 0.5% novocaine solution, depending on the age at a dose of 1.0-2.0 ml per kg of live body weight with adding 1.0 g of cefazolin in the region of the round ligament of the liver, the administration of novocaine solution with cefazolin. The injections are carried out in a cat in the supine position, at the point at 4.8-5.2 cm cranial to the umbilicus along the sagittal line of the abdomen in the dorsal direction. The puncture is made with the needle to the depth of 0.9-1.1 cm to the feeling of characteristic falling of the needle under the aponeurosis of the rectus abdominis muscle. The preparation solution is administered under pressure.

EFFECT: method is simple to use and highly effective for the treatment of acute hepatosis in cats.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention may be used for prevention of intrahepatic portal hypertension (IPH) in residual tissue of liver in patiens after hepatectomy (HE) of the different volume. That is ensured by an ultrasonography to determine a spleen area to be taken as an original size with underlying standard postoperative therapy in the first postoperative hours. Serotonine adipinate is administered intravenously drop-by-drop in a dose of 5-10 mg an hour with a spleen size monitored periodically. Administering the preparation is terminated if observing a decrease of the spleen area by not less than 10% of the original size.

EFFECT: improved blood circulation in the residual tissue of the liver, prevented IPH decreasing thereby a mortality of the given group of patients.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves a dietary therapy, taking mineral water in an amount of 100-150 ml, 3 times a day and exposure to a physical factor. What is used is the Pevzner's diet No. 5. Karachinskaya chloride-hydrocarbonate sodium gas-free mineral water of total mineralisation up to 3 g/dm3, at a temperature of 38-40°C is taken 30-40 minutes before a meal. The physical factor represents a magnetic laser therapy and an EHF therapy. The contact magnetic laser therapy covers three zones sequentially at a frequency of 5 Hz: an epigastric zone and the right and left upper hypochondria along the midclavicular lines, for 4 minutes for each zone within the course of 10 procedures. The EHF therapy involves combined exposure on two projection zones: in the right hypochondrium and on the sternum generated by a broadband noise emitter at an emission frequency of 40-63 GHz, for 20 minutes, every day within the course of 10 procedures.

EFFECT: method provides more effective rehabilitation treatment following endoscopic cholecystectomy ensured by the early integrated therapeutic exposure.

2 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: vasoendothelial growth factor inhibitor is introduced intravitreally (pars plana). That is followed by one-stage subthreshold micropulse laser coagulation 30 minutes later of the entire macular region, except for a central avascular zone in staggered circular lines. Distances of the laser coagulates in the entire area of exposure are equal to one coagulate. A laser processing of a perimacular area is further performed with a double distance of the laser coagulates and at lesser radiation power up to 800 mW short of 500 mcm to temporal vascular arcade in diabetic retinopathy, or upper or lower half of the perimacular area in thrombosis of a central retinal vein branch. The method provides higher early clinical effectiveness in the macular oedema until observing irreversible changes and stable visual deterioration, recovering the visual functions of the central retina by the atraumatic effect of the above laser parameters, treating the entire ischemic area and vascular retinal leakage.

EFFECT: administering vasoendothelial growth factor inhibitor provides recovery of the disturbed cytoarchitectonics of the evascular wall, reducing its permeability and transudation, desolating all the new vessels, reducing secondary oedemas of the optic disk.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely traumatology, orthopaedics, and can be used for supporting treatment in large joint replacement. That is ensured by determining a volume of involved joint contracture six months before the operation. That is followed by X-ray and magnetic resonant examination of the involved and collateral joints to specify their state. Besides, a quality of the bone tissue is assessed by osteodensitometry. If observing changes in the bone tissue quality, the complex of the drug therapy is added with the preparations Bivalos and Calcemin. A pain syndrome intensity is assessed by the visual analogue scale three months before the operation. That is followed by the complex therapy aiming at optimising the state of extremity joints with added local injection therapy (LIT). That is ensured by preliminary exposing the biologically active periarticular zones in the proximal and distal direction from the involved joint to the focused infrared laser light. A mixture containing solutions of the therapeutic preparations: chondroprotectors, Contrykal, Lidocaine, vitamin B12 is injected into the same zones. Besides, Arthrofoon is administered for the whole preoperative period. If the pain syndrome intensity is less than 4 points, Arthrofoon is administered in a dose of 4 tablets a day. If the intensity value is more than 4 points, the preparation is administered in a dose of 8 tablets a day in a complex with a short course of a non-steroidal anti-inflammatory preparations and a chondroprotector. The replacement operation is immediately followed by fixing a collateral joint with an orthesis for the period of 3 months. The complex of the postoperative supporting therapy started three weeks after the operation is added with a single intravenous introduction of the preparation Aklasta, the preparation Arthrofoon in a dose of 4 tablets a day for three months, alpha calcidole and Calcemin continuously. A pectoral girdle of the extremities is reinforced by means of an individually specified set of therapeutic exercises and electric walking myostimulation. The LIT of the collateral joint is performed three months after the operation. If observing a degenerative process in the adjacent joints, the LIT is performed alternatively in these regions. Vasodilators, chondroprotectors, and the preparation Milgamma are administered with underlying LIT. If observing psychoemotional changes in the patient, the preparation Tenoten is additionally administered. A postoperative medication regimen, including the LIT is repeated 3-4 times every 6 months.

EFFECT: method provides optimising the effect of the surgical management and preventing developing complications both in the operated joint, and in the adjacent and symmetrical joints after the replacement, preventing developing instability of the endoprosthesis components, preventing developing or aggravating degenerative process in the symmetrical and adjacent joints that reduces a risk of the recurrent operations.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to immunology. Claimed are versions of applying versions of sets of genes (pharmacodynamic (PD) markers) with increased regulation of expression or action, induced by alpha interferon (αIFN). Described are versions of method of identifying patients for obtaining MEDI-545 by identification of such profiles of expression of αIFN-induced FD markers.

EFFECT: application of invention ensures identification of patients, for which treatment with neutralising antibody MEDI-545 can be really effective, which can be applied in medicine.

10 cl, 90 dwg, 33 tbl, 22 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a composition containing a c-Met antagonist representing an antibody, and an aminoheteroaryl compound and applicable for treating cancer. Besides, the group of inventions represents a pharmaceutical composition containing an anti-c-Met antibody and the aminoheteroaryl compound in the form of combination medications.

EFFECT: using the group of inventions provides more effective inhibition of cancer growth and prolonged absence of a tumour.

15 cl, 2 dwg, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to methods for reducing B-cell count or treating a disease or disorder related to pathological activity of B-cells. That is ensured by administering a therapeutically effective amount of CD37-specific binding molecule and a therapeutically effective amount of mTOR or PI3K inhibitor into an individual. There are also presented a composition and a kit for treating non-Hodgkin lymphoma.

EFFECT: group of inventions provides a synergetic effect in administering CD37-specific binding molecules (SMIP) in a combination with mTOR or PI3K inhibitors for treating or preventing the B-cell related hyperproliferative disease.

36 cl, 9 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns using a peptide conjugated with a protein representing a keyhole limpet hemocyanin (KLH) protein used as an immunogen for preparing antibodies specifically recognising any of prevailing versions of beta-amyloid peptide Aβ40 and Aβ42; or using an antibody, or an active fragment, or an antibody derivative of the above peptide in preparing a therapeutic agent for preventing and/or treating a disease characterised by amyloid accumulation in the patient's brain.

EFFECT: group of inventions provides effective immunisation, reduces an amyloid load and a quantity of brain amyloid plaques.

5 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to experimental cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering a mixture of solutions of homoeopathic dilutions of monoclonal antibodies to vascular endothelium growth factor (VEGF) intragastrically into Wistar white male rats 2 times a day in a dose of 4.5 mg/kg for 28 days with underlying intraperitoneal administration of L-NAME in a dose of 12.5 mg/kg a day.

EFFECT: administering homoeopathic dilutions of monoclonal antibodies to VEGF prevents developing L-NAME induced endothelial dysfunction.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to experimental cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering a mixture of solutions of homoeopathic dilutions of monoclonal antibodies to interleukin-1 intragastrically into Wistar white male rats 2 times a day in a dose of 4.5 mg/kg for 28 days with underlying intraperitoneal administration of L-NAME in a dose of 12.5 mg/kg a day.

EFFECT: administering homoeopathic dilutions of monoclonal antibodies to interleukin-1 prevents developing L-NAME induced endothelial dysfunction.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering an activated potentiated form of vascular endothelial growth factor (VEGF) antibodies in an effective amount.

EFFECT: correction of endothelial dysfunction.

5 cl, 1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology. Claimed is a method of obtaining a high-titre antimicrobial serum. Method includes application of strain S.aureus No1991, characterised by immunogenicity ED50=(50-100)×106 microbial cells, weak virulence LD50=(0.5-2.0)×109 microbial cells; its inactivation and drying with dimethylketone by double processing with 3 volumes of dimethylketone. After that, immunisation of animals is carried out: two times subcutaneously and two times intravenously. In conclusion serum isolation is carried out.

EFFECT: invention can be used in medicine for estimation of antigen activity of anti-staphylococcal vaccines.

3 tbl

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

Up!